The same shot that protects against this year's flu strain might one day protect against a strain that has not emerged yet. That is the goal behind an AI-designed universal influenza vaccine that has now cleared its first human clinical trial, according to a report by Fox News.
The vaccine was developed using artificial intelligence to identify a target on the influenza virus that remains stable across different strains. Most flu vaccines are updated each year because the outer surface of the virus mutates rapidly. This experimental vaccine instead targets a region that does not change, which is why researchers believe it could work against future strains, including ones that might cause pandemics.
The trial tested the vaccine in human participants for the first time. Passing a first human clinical trial, known as a Phase 1 trial, means researchers are primarily checking whether the vaccine is safe and whether the body produces an immune response. It does not yet confirm the vaccine prevents flu in the general population. That would require larger and longer studies.
The AI component of the research involved analyzing large amounts of viral data to pinpoint which parts of the virus to target. Researchers used that analysis to design a vaccine candidate that could theoretically work across many different influenza strains, not just the ones currently circulating.
Scientists have been working toward a universal flu vaccine for decades. Seasonal flu kills hundreds of thousands of people globally each year, and a pandemic strain could be far more deadly. The 1918 influenza pandemic killed an estimated 50 million people worldwide. A vaccine that does not need to be reformulated each year and that could work against novel strains would represent a major shift in how the world prepares for flu outbreaks.
The use of artificial intelligence in vaccine design is a relatively recent development. AI tools were also used during the COVID-19 pandemic to accelerate research, and the technology has since been applied to cancer treatments, drug discovery, and other areas of medicine. This trial marks one of the more advanced applications of AI to influenza vaccine development.
Researchers will need to conduct additional trials with larger groups of participants to determine how well the vaccine actually prevents infection and how long any protection lasts. Those trials typically take several years. If the vaccine continues to show promise, it could eventually move toward regulatory review, though that process is also lengthy.
The findings add to growing interest in using AI to solve longstanding problems in infectious disease research. Whether this particular candidate reaches the market remains to be seen, but its progress through a first human trial is considered a significant step in the development process.
